DK2016198T3 - Method for predicting a risk of adverse drug reacting by determination of hla-b 1502 - Google Patents
Method for predicting a risk of adverse drug reacting by determination of hla-b 1502Info
- Publication number
- DK2016198T3 DK2016198T3 DK07797432.7T DK07797432T DK2016198T3 DK 2016198 T3 DK2016198 T3 DK 2016198T3 DK 07797432 T DK07797432 T DK 07797432T DK 2016198 T3 DK2016198 T3 DK 2016198T3
- Authority
- DK
- Denmark
- Prior art keywords
- hla
- predicting
- risk
- determination
- adverse drug
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80012106P | 2006-05-11 | 2006-05-11 | |
| PCT/US2007/068782 WO2007134235A2 (en) | 2006-05-11 | 2007-05-11 | Hla alleles associated with adverse drug reactions and methods for detecting such |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2016198T3 true DK2016198T3 (en) | 2013-07-15 |
Family
ID=38694734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07797432.7T DK2016198T3 (en) | 2006-05-11 | 2007-05-11 | Method for predicting a risk of adverse drug reacting by determination of hla-b 1502 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7943309B2 (da) |
| EP (1) | EP2016198B1 (da) |
| JP (1) | JP2009536828A (da) |
| KR (1) | KR101450348B1 (da) |
| CN (1) | CN101454462A (da) |
| AU (1) | AU2007249225B2 (da) |
| BR (1) | BRPI0710436A8 (da) |
| CA (1) | CA2651954C (da) |
| DK (1) | DK2016198T3 (da) |
| ES (1) | ES2422735T3 (da) |
| IL (1) | IL194900A (da) |
| MY (1) | MY150648A (da) |
| NZ (2) | NZ597628A (da) |
| PL (1) | PL2016198T3 (da) |
| PT (1) | PT2016198E (da) |
| TW (1) | TWI335937B (da) |
| WO (1) | WO2007134235A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| TWI498461B (zh) | 2010-04-12 | 2015-09-01 | Univ Nat Yang Ming | 利用人類白血球抗原(hla)篩檢預測藥物不良反應之方法 |
| JP5959634B2 (ja) * | 2011-06-23 | 2016-08-02 | チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン | フェニトインによって誘発される薬の副作用のリスク評価 |
| CN102296109A (zh) * | 2011-06-30 | 2011-12-28 | 北京思尔成生物技术有限公司 | HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒 |
| US20150225788A1 (en) | 2011-12-12 | 2015-08-13 | Wen-Hung Chung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN102660635B (zh) * | 2012-01-14 | 2014-03-12 | 长沙三济生物科技有限公司 | 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒 |
| CN103114138B (zh) * | 2013-01-27 | 2014-12-03 | 复旦大学 | Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒 |
| US10041121B2 (en) * | 2013-09-17 | 2018-08-07 | Agency For Science, Technology And Research | Method for detection of a genetic variant |
| CN104017898B (zh) * | 2014-06-25 | 2016-04-27 | 上海荻硕贝肯生物科技有限公司 | 快速检测hla-b*5801等位基因的引物、试剂盒及方法 |
| CN104232781B (zh) * | 2014-09-26 | 2017-04-19 | 陕西佰美基因股份有限公司 | 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法 |
| CN106119362B (zh) * | 2016-06-30 | 2019-09-10 | 江苏伟禾生物科技有限公司 | 一种用于检测hla-b*1502等位基因的引物组及试剂盒 |
| CN108929902B (zh) * | 2018-07-28 | 2022-03-25 | 北京博奥晶典生物技术有限公司 | 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法 |
| CN109355358A (zh) * | 2018-10-22 | 2019-02-19 | 江苏美因康生物科技有限公司 | 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法 |
| CN109554460B (zh) * | 2018-12-17 | 2022-03-22 | 上海市疾病预防控制中心 | 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途 |
| TWI804620B (zh) * | 2019-05-06 | 2023-06-11 | 長庚醫療財團法人林口長庚紀念醫院 | 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途 |
| US20220259655A1 (en) * | 2019-05-06 | 2022-08-18 | Chang Gung Memorial Hospital, Linkou | Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof |
| CN111620924A (zh) * | 2020-06-04 | 2020-09-04 | 华中农业大学 | 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用 |
| CN113308532A (zh) * | 2021-05-28 | 2021-08-27 | 上海康黎诊断技术有限公司 | 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒,以及方法 |
| WO2023080478A1 (ko) * | 2021-11-02 | 2023-05-11 | 주식회사 랩 지노믹스 | Hla-b*5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| EP0689609B2 (en) * | 1993-03-18 | 2005-04-13 | N.V. Innogenetics S.A. | Process for typing hla-b using specific primers and probes sets |
| US5550039A (en) * | 1995-03-07 | 1996-08-27 | Hoffmann-La Roche Inc. | Oligonucleotide primers for HLA class I B locus DNA typing |
| US6583139B1 (en) * | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US7638510B2 (en) * | 2003-02-17 | 2009-12-29 | Novartis Ag | Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| US7470513B2 (en) * | 2003-11-10 | 2008-12-30 | Academia Sinica | Risk assessment for adverse drug reactions |
-
2007
- 2007-05-11 NZ NZ597628A patent/NZ597628A/xx not_active IP Right Cessation
- 2007-05-11 WO PCT/US2007/068782 patent/WO2007134235A2/en not_active Ceased
- 2007-05-11 PL PL07797432T patent/PL2016198T3/pl unknown
- 2007-05-11 KR KR1020087027562A patent/KR101450348B1/ko active Active
- 2007-05-11 AU AU2007249225A patent/AU2007249225B2/en not_active Ceased
- 2007-05-11 TW TW096116910A patent/TWI335937B/zh active
- 2007-05-11 MY MYPI20084331 patent/MY150648A/en unknown
- 2007-05-11 DK DK07797432.7T patent/DK2016198T3/da active
- 2007-05-11 ES ES07797432T patent/ES2422735T3/es active Active
- 2007-05-11 PT PT77974327T patent/PT2016198E/pt unknown
- 2007-05-11 NZ NZ572259A patent/NZ572259A/en not_active IP Right Cessation
- 2007-05-11 CA CA2651954A patent/CA2651954C/en active Active
- 2007-05-11 US US11/747,674 patent/US7943309B2/en active Active
- 2007-05-11 JP JP2009510183A patent/JP2009536828A/ja active Pending
- 2007-05-11 BR BRPI0710436A patent/BRPI0710436A8/pt not_active Application Discontinuation
- 2007-05-11 EP EP07797432.7A patent/EP2016198B1/en not_active Revoked
- 2007-05-11 CN CNA2007800170212A patent/CN101454462A/zh active Pending
-
2008
- 2008-10-23 IL IL194900A patent/IL194900A/en active IP Right Grant
-
2011
- 2011-05-04 US US13/100,665 patent/US8142999B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007134235A2 (en) | 2007-11-22 |
| JP2009536828A (ja) | 2009-10-22 |
| BRPI0710436A8 (pt) | 2018-06-26 |
| EP2016198B1 (en) | 2013-05-01 |
| KR101450348B1 (ko) | 2014-10-14 |
| CN101454462A (zh) | 2009-06-10 |
| TWI335937B (en) | 2011-01-11 |
| WO2007134235A3 (en) | 2008-01-17 |
| EP2016198A2 (en) | 2009-01-21 |
| MY150648A (en) | 2014-02-14 |
| PT2016198E (pt) | 2013-07-29 |
| AU2007249225B2 (en) | 2013-06-27 |
| IL194900A0 (en) | 2009-08-03 |
| US20110212439A1 (en) | 2011-09-01 |
| IL194900A (en) | 2013-02-28 |
| ES2422735T3 (es) | 2013-09-13 |
| TW200844238A (en) | 2008-11-16 |
| BRPI0710436A2 (pt) | 2012-10-09 |
| PL2016198T3 (pl) | 2013-12-31 |
| KR20090031671A (ko) | 2009-03-27 |
| US8142999B2 (en) | 2012-03-27 |
| US7943309B2 (en) | 2011-05-17 |
| NZ597628A (en) | 2013-07-26 |
| NZ572259A (en) | 2012-03-30 |
| EP2016198A4 (en) | 2010-07-21 |
| US20080145846A1 (en) | 2008-06-19 |
| CA2651954A1 (en) | 2007-11-22 |
| AU2007249225A1 (en) | 2007-11-22 |
| CA2651954C (en) | 2014-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2016198T3 (en) | Method for predicting a risk of adverse drug reacting by determination of hla-b 1502 | |
| IL189690A0 (en) | A method for evaluation of a gemstone | |
| IL179344A (en) | Mobile Platform Tracking Method | |
| PL2029967T3 (pl) | Sposób pomiaru przedmiotu | |
| ZA200903889B (en) | Process for the synthesis of moxifloxacin hydrochloride | |
| AP2786A (en) | A method of agglomeration | |
| EP1928209A4 (en) | METHOD FOR MANUFACTURING A SPEAKER | |
| ZA200804555B (en) | A method for production of a coated endovascular device | |
| PL2043811T3 (pl) | Sposób wytwarzania części obiciowej | |
| IL198259A0 (en) | Process for the sulfinylation of a pyrazole derivative | |
| SG131081A1 (en) | Method for separating parts from a substrate | |
| IL181484A0 (en) | A method for evaluation of a gemstone | |
| EP1889002A4 (en) | Diffraction method for measuring the thickness of a working part | |
| ZA200808830B (en) | A method of depicting an image | |
| IL198260A0 (en) | Process for the sulfinylation of a pyrazole derivative | |
| GB0604660D0 (en) | Assay for phospholipidosis | |
| EP2081576A4 (en) | METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES | |
| GB2456690B (en) | A method for quantitative detection of diabetes related immunological markers | |
| IL194459A0 (en) | A method for assaying antigens | |
| EP2011001A4 (en) | METHOD FOR DETERMINING THE MOST PROBABLE K LOCATION | |
| FI20060916L (fi) | Menetelmä kauraa sisältävän taikinan valmistamiseksi | |
| GB0621886D0 (en) | Method for making a shoe | |
| GB0712702D0 (en) | A method for providing measurement gaps | |
| TWI317857B (en) | Method for updating the timing of a baseboard management controller | |
| IL195058A0 (en) | Duloxetine hcl polymorphs |